

# Jean-Yves Cahn

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3523829/publications.pdf>

Version: 2024-02-01

228  
papers

14,130  
citations

38742

50  
h-index

20961

115  
g-index

231  
all docs

231  
docs citations

231  
times ranked

11312  
citing authors

#	ARTICLE	IF	CITATIONS
1	Autologous Bone Marrow Transplantation as Compared with Salvage Chemotherapy in Relapses of Chemotherapy-Sensitive Non-Hodgkin's Lymphoma. <i>New England Journal of Medicine</i> , 1995, 333, 1540-1545.	27.0	2,253
2	High-Dose Therapy and Autologous Bone Marrow Transplantation after Failure of Conventional Chemotherapy in Adults with Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma. <i>New England Journal of Medicine</i> , 1987, 316, 1493-1498.	27.0	767
3	Long-Term Survival and Late Deaths after Allogeneic Bone Marrow Transplantation. <i>New England Journal of Medicine</i> , 1999, 341, 14-21.	27.0	666
4	IBMTR Severity INDEX FOR GRADING ACUTE GRAFT-VERSUS-HOST DISEASE: RETROSPECTIVE COMPARISON WITH GLUCKSBERG GRADE. <i>British Journal of Haematology</i> , 1997, 97, 855-864.	2.5	605
5	Risk factors for acute GVHD and survival after hematopoietic cell transplantation. <i>Blood</i> , 2012, 119, 296-307.	1.4	559
6	Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. <i>Lancet Oncology</i> , The, 2014, 15, 986-996.	10.7	549
7	Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. <i>Blood</i> , 2002, 100, 406-414.	1.4	503
8	Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors. <i>Lancet</i> , The, 1996, 348, 573-577.	13.7	440
9	Hematopoietic Stem-Cell Transplantation for Acute Leukemia in Relapse or Primary Induction Failure. <i>Journal of Clinical Oncology</i> , 2010, 28, 3730-3738.	1.6	386
10	Randomized Trial of Bone Marrow Versus Lenograstim-Primed Blood Cell Allogeneic Transplantation in Patients With Early-Stage Leukemia: A Report From the Soci�t� Fran�saise de Greffe de Moelle. <i>Journal of Clinical Oncology</i> , 2000, 18, 537-537.	1.6	357
11	Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia. <i>New England Journal of Medicine</i> , 2016, 375, 1044-1053.	27.0	270
12	Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia. <i>Blood</i> , 2015, 125, 2486-2496.	1.4	233
13	Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience. <i>Blood</i> , 2010, 115, 1690-1696.	1.4	232
14	Comparison of Preparative Regimens in Transplants for Children With Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2000, 18, 340-340.	1.6	222
15	Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. <i>Nature Medicine</i> , 2018, 24, 282-291.	30.7	216
16	Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States. <i>Blood</i> , 2017, 130, 1156-1164.	1.4	210
17	Toward a "NOTCH1/FBXW7/RAS/PTEN"-Based Oncogenetic Risk Classification of Adult T-Cell Acute Lymphoblastic Leukemia: A Group for Research in Adult Acute Lymphoblastic Leukemia Study. <i>Journal of Clinical Oncology</i> , 2013, 31, 4333-4342.	1.6	202
18	Chronic graft-versus-host disease after allogeneic blood stem cell transplantation: long-term results of a randomized study. <i>Blood</i> , 2002, 100, 3128-3134.	1.4	174

#	ARTICLE	IF	CITATIONS
19	Soft-Tissue Sarcoma and Non-Hodgkin's Lymphoma Clusters around a Municipal Solid Waste Incinerator with High Dioxin Emission Levels. <i>American Journal of Epidemiology</i> , 2000, 152, 13-19.	3.4	162
20	Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results. <i>Blood</i> , 2008, 111, 1078-1084.	1.4	156
21	Comparison of High-Dose Therapy and Autologous Stem-Cell Transplantation With Conventional Therapy for Hodgkin's Disease Induction Failure: A Case-Control Study. <i>Journal of Clinical Oncology</i> , 1999, 17, 222-222.	1.6	147
22	Long-Term Follow-Up of the Imatinib GRAAPH-2003 Study in Newly Diagnosed Patients with De Novo Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A GRAALL Study. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 150-155.	2.0	140
23	Reduced-Intensity Hematopoietic Cell Transplantation for Patients with Primary Myelofibrosis: A Cohort Analysis from the Center for International Blood and Marrow Transplant Research. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 89-97.	2.0	130
24	Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis. <i>Blood</i> , 2011, 117, 6714-6720.	1.4	128
25	Reduced-intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumors. <i>Blood</i> , 2004, 103, 435-441.	1.4	125
26	Acute Myeloid Leukemia With Translocation (8;21) or Inversion (16) in Elderly Patients Treated With Conventional Chemotherapy: A Collaborative Study of the French CBF-AML Intergroup. <i>Journal of Clinical Oncology</i> , 2009, 27, 4747-4753.	1.6	123
27	Impact of eculizumab treatment on paroxysmal nocturnal hemoglobinuria: a treatment versus no-treatment study. <i>American Journal of Hematology</i> , 2016, 91, 366-370.	4.1	110
28	Diagnosis of Toxoplasmosis after Allogeneic Stem Cell Transplantation: Results of DNA Detection and Serological Techniques. <i>Clinical Infectious Diseases</i> , 2009, 48, e9-e15.	5.8	107
29	Allogeneic haematopoietic stem cell transplantation for myelofibrosis: a report of the Soci�t� Fran�saise de Greffe de Moelle et de Therapie Cellulaire (SFGM�TC). <i>British Journal of Haematology</i> , 2011, 152, 331-339.	2.5	104
30	Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia. <i>Blood</i> , 2011, 118, 6030-6036.	1.4	103
31	Pregnancy after Hematopoietic Cell Transplantation: A Report from the Late Effects Working Committee of the Center for International Blood and Marrow Transplant Research (CIBMTR). <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 157-166.	2.0	91
32	Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission. <i>Blood Advances</i> , 2019, 3, 1826-1836.	5.2	89
33	Allogeneic Hematopoietic Stem-Cell Transplantation After Nonmyeloablative Preparative Regimens: Impact of Pretransplantation and Posttransplantation Factors on Outcome. <i>Journal of Clinical Oncology</i> , 2001, 19, 3340-3349.	1.6	87
34	Impact of posttransplantation G-CSF on outcomes of allogeneic hematopoietic stem cell transplantation. <i>Blood</i> , 2006, 107, 1712-1716.	1.4	85
35	Use of Donor T-Lymphocytes Expressing Herpes-Simplex Thymidine Kinase in Allogeneic Bone Marrow Transplantation: A Phase II Study. <i>Laboratoire d'Histocompatibilit� et Therapie Immuno-Mol�culaire, Besan�on, France. Human Gene Therapy</i> , 1997, 8, 615-624.	2.7	82
36	Effect of granulocyte colony-stimulating factor mobilization on phenotypical and functional properties of immune cells. <i>Experimental Hematology</i> , 2001, 29, 458-470.	0.4	81

#	ARTICLE	IF	CITATIONS
37	Classifying Cytogenetics in Patients with Acute Myelogenous Leukemia in Complete Remission Undergoing Allogeneic Transplantation: A Center for International Blood and Marrow Transplant Research Study. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 280-288.	2.0	81
38	Improved survival after acute graft-versus-host disease diagnosis in the modern era. <i>Haematologica</i> , 2017, 102, 958-966.	3.5	79
39	Addition of Gemtuzumab Ozogamycin to Chemotherapy Improves Event-Free Survival but Not Overall Survival of AML Patients with Intermediate Cytogenetics Not Eligible for Allogeneic Transplantation. Results of the GOELAMS AML 2006 IR Study. <i>Blood</i> , 2011, 118, 79-79.	1.4	77
40	c-Flip protein expression in Burkitt's lymphomas is associated with a poor clinical outcome. <i>British Journal of Haematology</i> , 2005, 128, 767-773.	2.5	72
41	How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients?. <i>Blood Advances</i> , 2019, 3, 4238-4251.	5.2	72
42	Intravenous Busulfan Compared with Total Body Irradiation Pretransplant Conditioning for Adults with Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 726-733.	2.0	71
43	The impact of the graft-versus-leukemia effect on survival in acute lymphoblastic leukemia. <i>Blood Advances</i> , 2019, 3, 670-680.	5.2	71
44	Increased risk of non-Hodgkin lymphoma and serum organochlorine concentrations among neighbors of a municipal solid waste incinerator. <i>Environment International</i> , 2011, 37, 449-453.	10.0	65
45	No impact of high-dose cytarabine on the outcome of patients transplanted for acute myeloblastic leukaemia in first remission. <i>British Journal of Haematology</i> , 2000, 110, 308-314.	2.5	64
46	Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome. <i>Journal of Clinical Oncology</i> , 2016, 34, 1864-1871.	1.6	61
47	Variability of Voriconazole Plasma Concentrations after Allogeneic Hematopoietic Stem Cell Transplantation: Impact of Cytochrome P450 Polymorphisms and Comedications on Initial and Subsequent Trough Levels. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 2305-2314.	3.2	56
48	Unrelated Cord Blood Transplantation for Patients with Primary or Secondary Myelofibrosis. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1841-1846.	2.0	53
49	HLA-Identical Sibling Allogeneic Transplants versus Chemotherapy in Acute Myelogenous Leukemia with t(8;21) in First Complete Remission: Collaborative Study between the German AML Intergroup and CIBMTR. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 187-196.	2.0	51
50	Reduced-Intensity Conditioning before Allogeneic Hematopoietic Stem Cell Transplantation in Patients Over 60 Years: A Report from the SFGM-TC. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 289-294.	2.0	51
51	IN VIVO ALLOREACTIVE POTENTIAL OF EX VIVO-EXPANDED PRIMARY T LYMPHOCYTES1. <i>Transplantation</i> , 1998, 65, 1365-1370.	1.0	51
52	Second Solid Cancers after Allogeneic Hematopoietic Cell Transplantation Using Reduced-Intensity Conditioning. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1777-1784.	2.0	50
53	Long-Term Survival and Late Effects among One-Year Survivors of Second Allogeneic Hematopoietic Cell Transplantation for Relapsed Acute Leukemia and Myelodysplastic Syndromes. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 151-158.	2.0	49
54	Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era. <i>Blood</i> , 2012, 119, 4083-4090.	1.4	47

#	ARTICLE	IF	CITATIONS
55	Epidemiology of invasive fungal infections during induction therapy in adults with acute lymphoblastic leukemia: a GRAALL-2005 study. <i>Leukemia and Lymphoma</i> , 2017, 58, 586-593.	1.3	47
56	Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma. <i>Leukemia Research</i> , 2018, 74, 130-136.	0.8	47
57	Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group. <i>Haematologica</i> , 2017, 102, 85-93.	3.5	46
58	Early matched sibling hematopoietic cell transplantation for adult AML in first remission using an age-adapted strategy: long-term results of a prospective GOELAMS study. <i>Blood</i> , 2012, 119, 2943-2948.	1.4	45
59	Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis. <i>Cancer</i> , 2016, 122, 3005-3014.	4.1	45
60	Comparing Outcomes with Bone Marrow or Peripheral Blood Stem Cells as Graft Source for Matched Sibling Transplants in Severe Aplastic Anemia across Different Economic Regions. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 932-940.	2.0	43
61	The prognosis of CALM-AF10-positive adult T-cell acute lymphoblastic leukemias depends on the stage of maturation arrest. <i>Haematologica</i> , 2013, 98, 1711-1717.	3.5	41
62	Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 767-775.	2.0	41
63	Sibling versus Unrelated Donor Allogeneic Hematopoietic Cell Transplantation for Chronic Myelogenous Leukemia: Refined HLA Matching Reveals More Graft-versus-Host Disease but not Less Relapse. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 1475-1478.	2.0	39
64	Influence of internal and outdoor factors on filamentous fungal flora in hematology wards. <i>American Journal of Infection Control</i> , 2009, 37, 631-637.	2.3	39
65	A Closed Culture System for the Ex Vivo Transduction and Expansion of Human T Lymphocytes. <i>Stem Cells and Development</i> , 1998, 7, 205-215.	1.0	37
66	Allotransplantation for Patients Age $\geq 40$ Years with Non-Hodgkin Lymphoma: Encouraging Progression-Free Survival. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 960-968.	2.0	37
67	Randomized Phase II Study of Clofarabine-Based Consolidation for Younger Adults With Acute Myeloid Leukemia in First Remission. <i>Journal of Clinical Oncology</i> , 2017, 35, 1223-1230.	1.6	37
68	Impact of antithymocyte globulin doses in reduced intensity conditioning before allogeneic transplantation from matched sibling donor for patients with acute myeloid leukemia: a report from the acute leukemia working party of European group of Bone Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2018, 53, 431-437.	2.4	37
69	Composite GRFS and CRFS Outcomes After Adult Alternative Donor HCT. <i>Journal of Clinical Oncology</i> , 2020, 38, 2062-2076.	1.6	36
70	Nilotinib (Tasigna <sup>®</sup> ) and Low Intensity Chemotherapy for First-Line Treatment of Elderly Patients with BCR-ABL1-Positive Acute Lymphoblastic Leukemia: Final Results of a Prospective Multicenter Trial (EWALL-PH02). <i>Blood</i> , 2018, 132, 31-31.	1.4	36
71	Comparative Analysis of Calcineurin Inhibitor-Based Methotrexate and Mycophenolate Mofetil-Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 73-85.	2.0	35
72	Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia. <i>Blood Advances</i> , 2022, 6, 339-357.	5.2	35

#	ARTICLE	IF	CITATIONS
73	Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1459-1468.	2.0	35
74	Reactive oxygen species levels control NF- $\kappa$ B activation by low dose deferasirox in erythroid progenitors of low risk myelodysplastic syndromes. <i>Oncotarget</i> , 2017, 8, 105510-105524.	1.8	35
75	Intensive short term therapy with granulocyte-macrophage-colony stimulating factor support, similar to therapy for acute myeloblastic leukemia, does not improve overall results for adults with acute lymphoblastic leukemia. , 1999, 86, 1496-1505.		33
76	Effect of Postremission Therapy before Reduced-Intensity Conditioning Allogeneic Transplantation for Acute Myeloid Leukemia in First Complete Remission. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 202-208.	2.0	33
77	Avascular Necrosis of Bone after Allogeneic Hematopoietic Cell Transplantation in Children and Adolescents. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 587-592.	2.0	33
78	Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 248-257.	2.0	33
79	Improved Survival by Adding Lomustine to Conventional Chemotherapy for Elderly Patients With AML Without Unfavorable Cytogenetics: Results of the LAM-SA 2007 FILO Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 3203-3210.	1.6	32
80	Inflammation is a potential risk factor of voriconazole overdose in hematological patients. <i>Fundamental and Clinical Pharmacology</i> , 2019, 33, 232-238.	1.9	32
81	Dispersion Modeling as a Dioxin Exposure Indicator in the Vicinity of a Municipal Solid Waste Incinerator: A Validation Study. <i>Environmental Science &amp; Technology</i> , 2006, 40, 2149-2155.	10.0	30
82	Unrelated alternative donor transplantation for severe acquired aplastic anemia: a study from the French Society of Bone Marrow Transplantation and Cell Therapies and the EBMT Severe Aplastic Anemia Working Party. <i>Haematologica</i> , 2016, 101, 884-890.	3.5	30
83	GANCICLOVIR-SENSITIVE ACUTE GRAFT-VERSUS-HOST DISEASE IN MICE RECEIVING HERPES SIMPLEX VIRUS-THYMIDINE KINASE-EXPRESSING DONOR T CELLS IN A BONE MARROW TRANSPLANTATION SETTING. <i>Transplantation</i> , 2000, 69, 503-508.	1.0	29
84	Retrovirus-Mediated Transfer of the Herpes Simplex Type I Thymidine Kinase Gene in Alloreactive T Lymphocytes. <i>Human Gene Therapy</i> , 1998, 9, 73-80.	2.7	25
85	Double umbilical cord blood transplantation for hematological malignancies: A long-term analysis from the SFGM-TC registry. <i>Experimental Hematology</i> , 2013, 41, 924-933.	0.4	25
86	Factor XIII replacement in stem-cell transplant recipients with severe hemorrhagic cystitis: a report of four cases. <i>Transplantation</i> , 2002, 74, 1190-1192.	1.0	24
87	Early Immune Response Against Retrovirally Transduced Herpes Simplex Virus Thymidine Kinase-Expressing Gene-Modified T Cells Coinfused with a T Cell-Depleted Marrow Graft: An Altered Immune Response?. <i>Human Gene Therapy</i> , 2008, 19, 937-950.	2.7	23
88	Center for International Blood and Marrow Transplant Research Chronic Graft-versus-Host Disease Risk Score Predicts Mortality in an Independent Validation Cohort. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 640-645.	2.0	23
89	Dynamics of Epstein-Barr viral load after hematopoietic stem cell transplantation and effect of preemptive rituximab therapy. <i>Transplant Infectious Disease</i> , 2016, 18, 889-895.	1.7	23
90	Enhanced activation of B cells in a granulocyte colony-stimulating factor-mobilized peripheral blood stem cell graft. <i>British Journal of Haematology</i> , 2001, 114, 698-700.	2.5	22

#	ARTICLE	IF	CITATIONS
91	Administration of donor apoptotic cells: an alternative cell-based therapy to induce tolerance?1. Transplantation, 2003, 75, 43S-45S.	1.0	21
92	Comparison of High Doses of Total Body Irradiation in Myeloablative Conditioning before Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 2398-2407.	2.0	21
93	Peripheral Blood versus Bone Marrow from Unrelated Donors: Bone Marrow Allografts Have Improved Long-Term Overall and Graft-versus-Host Disease-Free, Relapse-Free Survival. Biology of Blood and Marrow Transplantation, 2019, 25, 270-278.	2.0	21
94	Maintenance Tyrosine Kinase Inhibitors Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia: A Center for International Blood and Marrow Transplant Research Study. Biology of Blood and Marrow Transplantation, 2020, 26, 472-479.	2.0	21
95	High-dose melphalan and autologous bone marrow transplant for relapsed acute leukaemia. Cancer Chemotherapy and Pharmacology, 1983, 10, 109-111.	2.3	20
96	Pretransplantation Consolidation Chemotherapy Decreases Leukemia Relapse after Autologous Blood and Bone Marrow Transplants for Acute Myelogenous Leukemia in First Remission. Biology of Blood and Marrow Transplantation, 2006, 12, 204-216.	2.0	20
97	Dramatic efficacy of low dose lenalidomide as single agent in a patient with refractory gastric non-human immunodeficiency virus-associated plasmablastic lymphoma. Leukemia and Lymphoma, 2015, 56, 2986-2988.	1.3	20
98	Graft Failure after T Cell Depleted HLA Identical Allogeneic Bone Marrow Transplantation: Risk Factors in Leukemic Patients. Leukemia and Lymphoma, 1993, 11, 359-368.	1.3	19
99	c-myc box II mutations in Burkitt's lymphoma-derived alleles reduce cell-transformation activity and lower response to broad apoptotic stimuli. Oncogene, 2001, 20, 6084-6094.	5.9	19
100	Genetic polymorphisms in <i>ARID5B</i> , <i>CEBPE</i> , <i>IKZF1</i> and <i>CDKN2A</i> in relation with risk of acute lymphoblastic leukaemia in adults: a <i>GRAALL</i> study. British Journal of Haematology, 2012, 159, 599-613.	2.5	18
101	Outcome of conditioning intensity in acute myeloid leukemia with monosomal karyotype in patients over 45 years old: A study from the acute leukemia working party ( <i>ALWP</i> ) of the <i>EBMT</i> European group of blood and marrow transplantation ( <i>EBMT</i> ). American Journal of Hematology, 2015, 90, 719-724.	4.1	18
102	Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs. Leukemia Research, 2017, 63, 34-40.	0.8	18
103	Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a <i>CIBMTR</i> report. Blood Advances, 2020, 4, 3180-3190.	5.2	18
104	Danger of Systemic Cyclosporine for Corneal Graft. Cornea, 2002, 21, 613-614.	1.7	17
105	Dyserythropoiesis evaluated by the RED score and hepcidin:ferritin ratio predicts response to erythropoietin in lower-risk myelodysplastic syndromes. Haematologica, 2019, 104, 497-504.	3.5	17
106	Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) In Adults With Philadelphia Chromosome (Ph)-Negative Acute Lymphoblastic Leukemia (ALL): Results From The Group For Research On Adult ALL ( <i>GRAALL</i> ). Blood, 2013, 122, 552-552.	1.4	17
107	Outcomes after Umbilical Cord Blood Transplantation for Myelodysplastic Syndromes. Biology of Blood and Marrow Transplantation, 2017, 23, 971-979.	2.0	16
108	Increasing Use of Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients Age 70 Years and Older: A <i>CIBMTR</i> Study of Trends and Outcomes. Biology of Blood and Marrow Transplantation, 2016, 22, S68-S69.	2.0	15

#	ARTICLE	IF	CITATIONS
109	The post-transplant cytogenetic response to interferon is a major determinant of survival after autologous stem cell transplantation for chronic myeloid leukaemia in chronic phase. <i>British Journal of Haematology</i> , 2002, 118, 762-770.	2.5	14
110	Impact of T Cell Dose on Outcome of T Cell-Replete HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1875-1883.	2.0	14
111	Association of Antiepileptic Medications with Outcomes after Allogeneic Hematopoietic Cell Transplantation with Busulfan/Cyclophosphamide Conditioning. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1424-1431.	2.0	14
112	Comparison of outcomes of HCT in blast phase of <i>BCR-ABL1</i> MPN with de novo AML and with AML following MDS. <i>Blood Advances</i> , 2020, 4, 4748-4757.	5.2	14
113	A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2139-2146.	2.0	14
114	Risk factors of BK viral hemorrhagic cystitis in allogenic hematopoietic stem cell transplantation. <i>Transplant Infectious Disease</i> , 2021, 23, e13601.	1.7	14
115	Ruxolitinib For Patients With Primary Or Secondary Myelofibrosis before Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT): A Retrospective Study Of The Soci�t� Fran�saise De Greffe De Moelle Et De Th�rapie Cellulaire (SFGM-TC). <i>Blood</i> , 2013, 122, 2111-2111.	1.4	14
116	SOLUBLE CD8, IL-2 RECEPTOR, AND TUMOR NECROSIS FACTOR-ALPHA LEVELS IN STEROID-RESISTANT ACUTE GRAFT-VERSUS-HOST DISEASE. <i>Transplantation</i> , 1991, 52, 475-479.	1.0	13
117	Bortezomib combined with low-dose cytarabine in Intermediate- and high risk myelodysplastic syndromes. A phase I/II Study by the GFM. <i>British Journal of Haematology</i> , 2012, 158, 232-237.	2.5	13
118	Providing Personalized Prognostic Information for Adult Leukemia Survivors. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1600-1607.	2.0	13
119	Graft-versus-host disease in recipients of male unrelated donor compared with parous female sibling donor transplants. <i>Blood Advances</i> , 2018, 2, 1022-1031.	5.2	13
120	An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis. <i>Bone Marrow Transplantation</i> , 2021, 56, 3068-3077.	2.4	13
121	The Upper Age Limit for a Pediatric-Inspired Therapy in Younger Adults with Ph-Negative Acute Lymphoblastic Leukemia (ALL)? Analysis of the Graall-2005 Study. <i>Blood</i> , 2016, 128, 762-762.	1.4	13
122	Comparison of Outcomes of Allogeneic Transplantation for Chronic Myeloid Leukemia with Cyclophosphamide in Combination with Intravenous Busulfan, Oral Busulfan, or Total Body Irradiation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 552-558.	2.0	12
123	The impact of anti-thymocyte globulin on the outcomes of Patients with AML with or without measurable residual disease at the time of allogeneic hematopoietic cell transplantation. <i>Leukemia</i> , 2020, 34, 1144-1153.	7.2	12
124	Extracellular vesicles from myelodysplastic mesenchymal stromal cells induce DNA damage and mutagenesis of hematopoietic stem cells through miRNA transfer. <i>Leukemia</i> , 2020, 34, 2249-2253.	7.2	11
125	Disease-Related Symptoms Reported across a Broad Population of Patients with Paroxysmal Nocturnal Hemoglobinuria.. <i>Blood</i> , 2007, 110, 3683-3683.	1.4	11
126	The Addition Of Gemtuzumab Ozogamicin (GO) To Induction Chemotherapy Reduces Relapse and Improves Survival In Patients Without Adverse Risk Karyotype: Results Of An Individual Patient Meta-Analysis Of The Five Randomised Trials. <i>Blood</i> , 2013, 122, 356-356.	1.4	11



#	ARTICLE	IF	CITATIONS
127	Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report. <i>Clinical Cancer Research</i> , 2019, 25, 5143-5155.	7.0	10
128	Inferior Outcomes with Cyclosporine and Mycophenolate Mofetil after Myeloablative Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1744-1755.	2.0	10
129	Post-Remission Therapy with Imatinib and HAM Improve MRD before Tansplant for Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ALL): Results of the GRAALL AFR03 Study.. <i>Blood</i> , 2006, 108, 1877-1877.	1.4	10
130	Allogeneic Stem Cell Tranplantation (allo-SCT) for Adult Patients with Active Refractory/Relapsed Hematological Malignancies: a Survey From the Societe Francaise De Greffe De Moelle Et De Therapie Cellulaire (SFGM-TC).. <i>Blood</i> , 2010, 116, 3456-3456.	1.4	10
131	Fludarabine Versus No-Treatment In the Patients with CLL Stage A. <i>Blood</i> , 2010, 116, 4639-4639.	1.4	10
132	A Single Intravenous Infusion of Apoptotic Cells, An Alternative Cell-Based Therapy Approach Facilitating Hematopoietic Cell Engraftment, Did Not Induce Autoimmunity. <i>Journal of Hematotherapy and Stem Cell Research</i> , 2003, 12, 451-459.	1.8	9
133	Development of autologous cytotoxic CD4+T clones in a human model of B-cell non-Hodgkin follicular lymphoma. <i>British Journal of Haematology</i> , 2006, 135, 324-335.	2.5	9
134	Mobile air-decontamination unit and filamentous fungal load in the hematology ward: How efficient at the low-activity mode?. <i>American Journal of Infection Control</i> , 2009, 37, 680-682.	2.3	9
135	Related Myeloablative Stem Cell Transplantation (SCT) to Cure Sickle Cell Anemia (SCA): Update of French Results. <i>Blood</i> , 2010, 116, 3518-3518.	1.4	9
136	Insomnia, Quality Of Life and MPN Symptom Burden: An Analysis By The MPN Quality Of Life International Study Group (MPN-QOL ISG). <i>Blood</i> , 2013, 122, 4087-4087.	1.4	9
137	Cost Effectiveness of Cardioprotective Strategies in Patients with Aggressive Non-Hodgkin??s Lymphoma. <i>Clinical Drug Investigation</i> , 2005, 25, 719-729.	2.2	8
138	Measurement of imatinib uptake by flow cytometry. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2012, 81A, 996-1004.	1.5	8
139	Tumor microenvironment and clonal monocytes from chronic myelomonocytic leukemia induce a procoagulant climate. <i>Blood Advances</i> , 2019, 3, 1868-1880.	5.2	8
140	Publi dans Hmatologie vol. 11, n1, janvier-fvrier 2005. <i>Hematologie</i> , 2014, 20, 12-21.	0.0	8
141	Interferon alpha therapy in haemophilic patients with chronic hepatitis C: a French multicentre pilot study of 58 patients. <i>European Journal of Gastroenterology and Hepatology</i> , 2001, 13, 859-864.	1.6	7
142	Endogenous megakaryocytic colonies underline association between megakaryocytes and calreticulin mutations in essential thrombocythemia. <i>Haematologica</i> , 2015, 100, e176-e178.	3.5	7
143	Adult patients with de novo acute myeloid leukemia show a functional deregulation of redox balance at diagnosis which is correlated with molecular subtypes and overall survival. <i>Haematologica</i> , 2019, 104, e393-e397.	3.5	7
144	Influence of alternative donor type on early survival after hematopoietic stem cell transplantation for acute myeloid leukemia lacking a sibling donor. <i>Bone Marrow Transplantation</i> , 2020, 55, 749-757.	2.4	7

#	ARTICLE	IF	CITATIONS
145	Outcome Of Patients With IPSS Intermediate (int) Or High Risk Myelodysplastic Syndrome (MDS) According To Donor Availability: A Multicenter Prospective Non Interventional Study For The SFGM-TC and GFM. <i>Blood</i> , 2013, 122, 301-301.	1.4	7
146	Cytomegalovirus infection and chronic graft-versus-host disease are significant predictors of renal failure after allogeneic hematopoietic stem cell transplantation. <i>Haematologica</i> , 2005, 90, 569-70.	3.5	7
147	Impact of body surface area on patients' outcome in younger adults with acute myeloid leukemia. <i>European Journal of Haematology</i> , 2017, 98, 443-449.	2.2	6
148	Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 2108-2117.	2.4	6
149	Myeloproliferative (MPN) Symptom Burden Response Thresholds: Assessment Of MPN-SAF TSS Quartiles As Potential Markers Of Symptom Response. <i>Blood</i> , 2013, 122, 4067-4067.	1.4	6
150	Sexuality Challenges, Intimacy, and MPN Symptom Burden: An Analysis By The MPN Quality Of Life International Study Group (MPN-QOL ISG). <i>Blood</i> , 2013, 122, 4088-4088.	1.4	6
151	Higher Doses of Antithymocyte Globulin (ATG) Increase the Risk of Relapse in Acute Myeloid Leukemia (AML) Patients Undergoing Matched Related Donor Allogeneic Transplantation in First Complete Remission (CR1): An Analysis from the Acute Leukemia Working Party of EBMT. <i>Blood</i> , 2014, 124, 729-729.	1.4	6
152	Quantitating Effector and Regulatory T Lymphocytes in Immune Responses by Limiting Dilution Analysis Modeling. <i>Journal of Immunology</i> , 2005, 174, 3421-3431.	0.8	5
153	Assessment of Impact of HLA Type on Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Lymphocytic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 581-586.	2.0	5
154	Lomustine is beneficial to older AML with ELN2017 adverse risk profile and intermediate karyotype: a FILO study. <i>Leukemia</i> , 2021, 35, 1291-1300.	7.2	5
155	Conditioning Intensity In Middle Aged Patients With AML In CR1. No Advantage For Myeloablative Regimens Irrespective Of The Risk Group. An Observational Analysis By The Acute Leukemia Working Party Of The EBMT. <i>Blood</i> , 2013, 122, 542-542.	1.4	5
156	EVIDENCE THAT A TRANSIENT ENHANCEMENT OF ENDOGENOUS HEMATOPOIESIS CONTRIBUTES SIGNIFICANTLY TO THE FAVORABLE OUTCOME FOLLOWING INTERLEUKIN 1 PRETREATMENT AND ALLOGENEIC BONE MARROW TRANSPLANTATION1. <i>Transplantation</i> , 1996, 61, 673-676.	1.0	4
157	Allogeneic Hematopoietic Stem Cell Transplantation Improves Outcome of Elderly Patients with Acute Myeloid Leukemia in First Complete Remission: A Time-Dependent and Multistate Analysis from the French Innovative Leukemia Organization. <i>Blood</i> , 2018, 132, 209-209.	1.4	4
158	The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) Derived Total Symptom Score (TSS): An International Trial of 1433 Patients with Myeloproliferative Neoplasms (MPNs). <i>Blood</i> , 2011, 118, 3839-3839.	1.4	4
159	Impact of High Body Surface Area on AML Outcome in Younger Patients: A Goelams Study. <i>Blood</i> , 2014, 124, 973-973.	1.4	4
160	Clofarabine-Based Consolidation Improves Relapse-Free Survival of Younger Adults with Non-Favorable Acute Myeloid Leukemia (AML) in First Remission: Results of the Randomized ALFA-0702/Clara Study (NCT 00932412). <i>Blood</i> , 2015, 126, 218-218.	1.4	4
161	Symptom Burden As Primary Driver for Therapy in Patients with Myelofibrosis: An Analysis By MPN International Quality of Life Study Group. <i>Blood</i> , 2016, 128, 3117-3117.	1.4	4
162	Essential Thrombocythemia (ET) and Polycythemia Vera (PV) Symptom Burden: Phenotypic Cluster Analysis Among an International Sample of 1,141 ET and PV Patients. <i>Blood</i> , 2012, 120, 1726-1726.	1.4	4

#	ARTICLE	IF	CITATIONS
163	Interleukin-2-induced increase of a monoclonal b-cell lymphocytosis. A novel In vivo interleukin-2 effect?. Cancer, 1992, 69, 2583-2588.	4.1	3
164	Reduced-Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) for Patients Aged >=60 Years: a Retrospective Study of 629 Patients From the Societe Française De Greffe De Moelle Et De Therapie Cellulaire (SFGM-TC).. Blood, 2009, 114, 194-194.	1.4	3
165	Arsenic Trioxide (ATO) In the Consolidation Treatment of Newly Diagnosed APL - First Interim Analysis of a Randomized Trial (APL 2006) by the French Belgian Swiss APL Group. Blood, 2010, 116, 505-505.	1.4	3
166	Outcomes After Unrelated Cord Blood Transplantation For Adults With Primary Or Secondary Myelofibrosis: A Retrospective Study On Behalf Of Eurocord and Chronic Malignancy Working Party-EBMT. Blood, 2013, 122, 2156-2156.	1.4	3
167	Symptom Burden Profile in Myelofibrosis Patients with Thrombocytopenia: Lessons and Unmet Needs. Blood, 2015, 126, 4080-4080.	1.4	3
168	Graft T-cell depletion as a prerequisite for the modulation of alloreactivity after haematopoietic stem cell transplantation. Transfusion Science, 1997, 18, 327-336.	0.6	2
169	Renal toxicity after bone marrow transplantation. International Journal of Radiation Oncology Biology Physics, 2004, 58, 661-662.	0.8	2
170	In vitro functional defects of bone marrow-derived CD34+ progenitors from newly diagnosed mature B-cell malignancies with bone marrow tumor involvement. Experimental Hematology, 2005, 33, 318-328.	0.4	2
171	Conventional chemotherapy for acute myeloid leukemia in older adults: Impact on nutritional, cognitive, and functional status. European Journal of Haematology, 2021, 106, 859-867.	2.2	2
172	Prognostic Value of the "Monosomal Karyotype" Entity in Elderly Patients with AML: a GOELAMS Study of 186 Patients with Unfavourable Cytogenetic Abnormalities.. Blood, 2009, 114, 1577-1577.	1.4	2
173	The Myelofibrosis Symptom Burden (MF-SB): An International Phenotypic Cluster Analysis of 329 Patients. Blood, 2012, 120, 1731-1731.	1.4	2
174	Safety and Efficacy Of Rituximab In adult's Immune Thrombocytopenia (ITP) : Results After One-Year Of Follow-Up In 252 Patients From The Prospective French ITP-Ritux Registry. Blood, 2013, 122, 450-450.	1.4	2
175	Symptom Severity and Clinical Variables of Polycythemia Vera Patients with Splenomegaly, Phlebotomy Requirements and/or Hydroxyurea Use: a Retrospective Evaluation of 1334 Patients. Blood, 2014, 124, 1848-1848.	1.4	2
176	Double Cord Blood Transplantation: Incidence, Organ Involvement and Risk Factors of Acute Graft Versus Host Disease. a Retrospective Analysis on Behalf of Eurocord, ALWP and Cqwp-EBMT. Blood, 2014, 124, 187-187.	1.4	2
177	Impact of Disease Duration upon Symptom Burden Amongst Patients with Myeloproliferative Neoplasms (MPNs). Blood, 2015, 126, 4073-4073.	1.4	2
178	Mechanisms of Improvement of Erythropoiesis with Low Dose Deferasirox in Low Risk Myelodysplastic Syndromes. Blood, 2016, 128, 3152-3152.	1.4	2
179	Antithymocyte Globulins (ATG) as Part of the Myeloablative Conditioning (MAC) Regimen Can Reduce the Risk of Severe Graft-Vs.-Host Disease (GVHD) after Allogeneic Stem Cell Transplantation (allo-SCT) from Matched-Unrelated Donors (MUD).. Blood, 2008, 112, 1151-1151.	1.4	2
180	Equivalent Outcome Between Older Siblings and Unrelated Donors After Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Patients Older Than 50 Years with Acute Myeloid Leukemia in First Complete Remission: A Report From the ALWP of EBMT. Blood, 2012, 120, 961-961.	1.4	2

#	ARTICLE	IF	CITATIONS
181	The Role of Anti-Thymocyte Globulin (ATG) in Patients with AML Transplanted in CR1 from Sibling and Unrelated Donors with or without Measurable Residual Disease (MRD) at the Time of Allogeneic Stem Cell Transplantation: a Study on Behalf of the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT). <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 648-649.	2.0	1
182	Effect of Rap-536 on MDS PDX-Murine Models with or without SF3B1 Mutation. <i>Blood</i> , 2019, 134, 1705-1705.	1.4	1
183	Genoidentical Donor Versus A, B, Cw, DR, DQ, HLA Allelic-Matched Unrelated Donor for Stem Cell Transplantation in Patients with Standard Risk Haematological Malignancy.. <i>Blood</i> , 2004, 104, 976-976.	1.4	1
184	Older Age, Use Of Myeloablative Regimens For Malignant Diseases and Chronic Graft-Versus-Host Disease Are Risk Factors For Avascular Necrosis Of Bone After Allogeneic Hematopoietic Cell Transplantation In Children and Adolescents. <i>Blood</i> , 2013, 122, 917-917.	1.4	1
185	Impact of Early Post-Transplant Complications on Survival of Patients with Myelodysplastic Syndrome Undergoing Allo-SCT Following Reduced Intensity Conditioning: An SFGM-TC Study. <i>Blood</i> , 2015, 126, 1922-1922.	1.4	1
186	Addition of Lomustine (CCNU) to Induction and Post-Remission Chemotherapy for Fit Elderly AML Patients without Unfavorable Cytogenetics: Results of the Lamsa-2007 Goelams Trial. <i>Blood</i> , 2015, 126, 3736-3736.	1.4	1
187	Safety and Long-Term Efficacy of Maintenance Therapy with Alternating Azacytidine (AZA) and Lenalidomide (Len) Cycles in Elderly (≥ 60) Fit Patients (Pts) with Poor Prognosis AML in First Complete Remission (CR) After LIA Induction. A Phase II Multicentric GOELAMS Trial. <i>Blood</i> , 2015, 126, 3787-3787.	1.4	1
188	Core Binding Factor Acute Myeloid Leukemia of the Elderly Treated with Conventional Chemotherapy: A Collaborative Study of the French CBF AML Intergroup. <i>Blood</i> , 2008, 112, 553-553.	1.4	1
189	Molecular Response, Efficacy and Safety Analysis of 168 Adult French Patients with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) From the ENACT (Expanding Nilotinib Access in Clinical Trials) Study.. <i>Blood</i> , 2009, 114, 3293-3293.	1.4	1
190	The Role of Total Body Irradiation (TBI) in the High-Dose Regimen of Patients with Follicular Lymphoma (FL) Treated with Autologous Stem Cell Transplant (ASCT) in the Rituximab Era. A Retrospective Study of the EBMT Lymphoma Working Party. <i>Blood</i> , 2011, 118, 502-502.	1.4	1
191	The Role of Anti-Thymocyte Globulin (ATG) in Patients with AML Transplanted in CR1 from Sibling and Unrelated Donors with or without Measurable Residual Disease (MRD) at the Time of Allogeneic Stem Cell Transplantation: A Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Blood</i> , 2018, 132, 248-248.	1.4	1
192	Long-Term Survival and Late Effects Among 1-Year Survivors of Second Allogeneic Hematopoietic Cell Transplantation (2nd Allo HCT) for Relapsed Acute Leukemia and Myelodysplastic Syndrome: A Report from the Cibmtr. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, S64.	2.0	0
193	Impact of Higher-Dose Total Body Irradiation Conditioning on Outcome of an Allogeneic Hematopoietic Cell Transplant (HCT) in the Modern Era. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, S94-S95.	2.0	0
194	Allogeneic Stem Cell Transplantation (allo-SCT) from a HLA Identical Sibling for CR1 AML Patients Aged above 55 Years Old after a Reduced Intensity Conditioning: A Survey from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).. <i>Blood</i> , 2005, 106, 1140-1140.	1.4	0
195	Thrombosis in Patients with Paroxysmal Nocturnal Hemoglobinuria.. <i>Blood</i> , 2007, 110, 3670-3670.	1.4	0
196	Reduced Intensity Allogeneic Stem Cell Transplantation for Follicular Lymphoma Results in An Improved Progression Free Survival When Compared to Autologous Stem Cell Transplantation. An Analysis from the Lymphoma Working Party of the EBMT. <i>Blood</i> , 2008, 112, 458-458.	1.4	0
197	Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) as a Curative Therapy in Primary and Secondary Myelofibrosis (MF): A 14-Year Period Oligocentric French Experience.. <i>Blood</i> , 2008, 112, 1756-1756.	1.4	0
198	Double Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation: French Society of Bone Marrow Graft Transplantation and Cellular Therapy Experience. <i>Blood</i> , 2008, 112, 4293-4293.	1.4	0

#	ARTICLE	IF	CITATIONS
199	Improved Outcome by Addition of Lomustine (CCNU) to Idarubicin and Cytarabine in Elderly Patients with De Novo Acute Myeloid Leukemia. A Report from the GOELAMS Group. Blood, 2008, 112, 761-761.	1.4	0
200	Allogeneic Stem Cell Immunotherapy for Advanced Metastatic Breast Cancer: Lessons from Experience. Blood, 2008, 112, 3903-3903.	1.4	0
201	Impact of Genetic Abnormalities After Allogeneic Stem Cell Transplantation in Multiple Myeloma: Report of the Societe Francaise De Greffe De Moelle Et De Therapie Cellulaire.. Blood, 2009, 114, 1187-1187.	1.4	0
202	Expression of S100A8 in Leukemic Cells Predicts Poor Survival in De Novo AML Patients.. Blood, 2009, 114, 276-276.	1.4	0
203	Improved Survival for 149 First-Line Multiple Myeloma (MM) Patients (pts) Treated by Tandem Autologous (Auto)/Allogeneic (Allo) Stem Cell Transplantation (SCT) : Retrospective Study of the Societe Francaise de Greffe de Moelle Therapie Cellulaire (SFGM-TC).. Blood, 2009, 114, 1188-1188.	1.4	0
204	Chronic Graft-Versus-Host Disease Risk Score: A CIBMTR Analysis. Blood, 2010, 116, 898-898.	1.4	0
205	Risk-Factors for Acute Graft-Versus-Host Disease and Survival After Hematopoietic Cell Transplantation From Siblings and Unrelated Donors " An Analysis of the CIBMTR. Blood, 2010, 116, 897-897.	1.4	0
206	Risk Factors for Major Transplant Related Outcomes In Pediatric Patients with Chronic Graft-Versus-Host Disease. Blood, 2010, 116, 211-211.	1.4	0
207	Therapy Related APL (tAPL). Prospective Analysis of Etiological Factors In Recent Cases, and Comparison with De Novo Cases. Blood, 2010, 116, 2171-2171.	1.4	0
208	Prognostic Impact of JAK2V617F Mutation In MDS: a Matched Case Control Study. Blood, 2010, 116, 440-440.	1.4	0
209	Phase 2 Study of Allogeneic Stem Cell Transplantation (ASCT) From Matched Related Donor (MRD) In Patients Older Than 55 Years After Reduced Intensity Conditioning (RIC) Associating Fludarabine, Intravenous Busulfan and Rabbit Thymoglobulin. Blood, 2010, 116, 1320-1320.	1.4	0
210	Cytogenetics Abnormalities Predict the Outcome of Allogeneic Transplantation In AML: A CIBMTR Study. Blood, 2010, 116, 680-680.	1.4	0
211	RAD001: A Clinico-Biological Phase I GOELAMS trial of Everolimus Association with High Dose Chemotherapy in Late Relapsing AML Patients Under 65 Years of Age. Blood, 2011, 118, 945-945.	1.4	0
212	Older Adults with Chronic Myelogenous Leukemia (CML), During the Tyrosine Kinase Inhibitor (TKI) Era, Can Be Successfully Treated with Reduced Intensity Conditioning (RIC) Hematopoietic Cell Transplant (HCT) Using Sibling or Unrelated Donors: A Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis. Blood, 2011, 118, 494-494.	1.4	0
213	Comparison of the Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) Across Nine Linguistic Translations Among an International Sample of 1,851 Myeloproliferative Neoplasm (MPN) Patients.. Blood, 2012, 120, 2852-2852.	1.4	0
214	Towards a Purely Oncogenetic Risk Classification of Adult T-ALL: a GRAALL Study. Blood, 2012, 120, 881-881.	1.4	0
215	Epidemiology Of Invasive Aspergillosis (IA) During Induction Therapy In Adults With Acute Lymphoblastic Leukemia (ALL): A Graall-2005 Study. Blood, 2013, 122, 1394-1394.	1.4	0
216	Effect of Immune Modulation for Peripheral T-Cell Lymphoma in Response to Relapse after Allogeneic Hematopoietic Stem Cell Transplant: A Study of 63 Patients By the French Society of Bone Marrow Transplantation and Cell Therapies (SFGM-TC).. Blood, 2014, 124, 3963-3963.	1.4	0

#	ARTICLE	IF	CITATIONS
217	Outcomes of Cord Blood Transplantation Using Reduced Intensity Conditioning for Chronic Lymphocytic Leukemia: A Retrospective Study on Behalf of Eurocord, SFGM-TC and Cqwp-EBMT. Blood, 2014, 124, 2581-2581.	1.4	0
218	Unrelated Alternative Donor Transplants for Severe Acquired Aplastic Anemia: A 12-Year Retrospective Study from the French Society of Bone Marrow Transplantation and Cell Therapies (SFGM-TC). Blood, 2014, 124, 2945-2945.	1.4	0
219	Impact of CD3+ and CD34+ Doses in the Mobilized Peripheral Blood Stem Cell Grafts on the Outcome of Reduced-Intensity Conditioning Allogeneic Transplantation from Matched Unrelated Donors for Acute Myeloid Leukemia " an Analysis from the Acute Leukemia Working Party of the EBMT. Blood, 2014, 124, 190-190.	1.4	0
220	Comparison of Matched/Mismatched Unrelated Donor Stem Cell Transplantation to Autologous Stem Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission: A Study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Blood, 2015, 126, 3216-3216.	1.4	0
221	Unmet Needs for Symptom Control in Essential Thrombocythemia with Front Line Therapy. Blood, 2015, 126, 5175-5175.	1.4	0
222	CloB2A2 Reduced-Intensity Conditioning (RIC) Regimen Prior to Allogeneic Stem Cell Transplantation Provides Significant Better Survival Compared to FB2A2 RIC Regimen in Adults with Acute Myeloid Leukemia (AML): A Study on Behalf of the SFGM-TC. Blood, 2015, 126, 1908-1908.	1.4	0
223	Efficacy and Safety of Immunosuppressive Therapy with Horse Antithymocyte Globulin (ATGAM) Plus Ciclosporine in 341 Patients with Acquired Aplastic Anemia: Report of the French Patient-Named Program on Behalf of the French Reference Center for Aplastic Anemia. Blood, 2016, 128, 5069-5069.	1.4	0
224	Association Between Multiple Mismatches at the HLA-DPB1 and DRB3/4/5 Genes and Adverse Outcomes in HLA-a, -B, -C, -DRB1 and -DQB1 Identical Hematopoietic Stem Cell Transplantation: A Study on Behalf of the Francophone Society of Stem Cell Transplantation and Cellular Therapy (SFGM-TC) and the Francophone Society for Histocompatibility and Immunogenetics (SFHI). Blood, 2016, 128, 4660-4660.	1.4	0
225	Consideration of Symptom Burden Based Treatment in PV and ET Patients: An Analysis By MPN International Quality of Life Study Group. Blood, 2016, 128, 5463-5463.	1.4	0
226	Outcome Analysis of High-Dose Chemotherapy Followed By Autologous Stem Cell Transplantation in Patients with Hodgkin Lymphoma: A Francophone Society of Bone Marrow Transplantation and Cellular Therapy Study. Blood, 2016, 128, 3458-3458.	1.4	0
227	Is Arsenic Trioxide (ATO) Required in the Treatment of High Risk Newly Diagnosed APL? Analysis of a Randomized Trial (APL2006) By the French Belgian Swiss APL Group. Blood, 2016, 128, 895-895.	1.4	0
228	Risk Factors of BK Virus Cystitis in Haematopoietic Stem Cell Transplantation-a Retrospective Monocentric Study. Blood, 2018, 132, 3361-3361.	1.4	0